Abstract 564P
Background
The current National Comprehensive Cancer Network guideline recommends Afatinib and/or Osimertinib as the preferred first-line treatment strategy for patients with advanced NSCLC carrying EGFR p.G719X mutation. In the absence of head-to-head trials comparing Afatinib with Osimertinib in EGFR p.G719X mutant patients, it is unclear which regimen is the preferred treatment option.
Methods
A large cohort of 4228 treatment-naïve patients with lung cancer who underwent targeted next-generation sequencing (NGS) testing was screened in terms of the EGFR p.G719X mutation. Ba/F3 cells stably expressing the EGFR p.G719A mutation with either the p.E709K mutation or not were created to investigate the response to EGFR-TKIs. The patient-derived lung cancer organoid (LCO) cultures were created, and the corresponding drug treatments and sensitivity (DTS) test was performed.
Results
EGFR p.G719X mutation occurs with a prevalence of 2.56%. EGFR p.E709X(30.4%) composed the most frequent co-occurring EGFR mutation. Co-occurring EGFR p.E709X mutations exerted a detrimental effect on outcomes in Osimertinib-treated patients (G719X/E709X VS. G719X; ORR: 0.00% VS. 47.62%, P<0.001; mPFS:7.18 VS. 14.2 months, P=0.042; respectively). In contrast, no significant difference was found in the treatment efficacy between EGFR p.G719X/E709X and EGFR p.G719X patients upon Afatinib treatment (G719X/E709X VS. G719X; ORR: 71.43% VS. 56.67%, P=0.99; mPFS:14.7 VS. 15.8 months, P=0.69; respectively). In vitro experiments elucidated a resistant drug sensitivity and poor inhibition of EGFR phosphorylation in Ba/F3 cells expressing EGFR p.G719A/E709K mutation treated with the third-generation EGFR-TKIs. The DTS result of LCO revealed that the second-generation EGFR-TKIs may be superior to first or third-generation EGFR-TKIs for patients with EGFR p.G719X/E709X mutation.
Conclusions
We enrolled the largest available dataset of EGFR p.G719X-mutant patients with NSCLC. The variable sensitivity of EGFR p.G719X mutation to different EGFR TKIs indicates that a personalized treatment strategy should be undertaken in patients depending on the status of underlying co-existing EGFR p.E709X mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract